24 okt: U.S. FDA grants orphan drug designation to glepaglutide for the t..
24 okt: Sanoma Improves its Outlook for 2017
24-10-2017 12:44:03

U.S. FDA grants orphan drug designation to glepaglutide for the treatment of short bowel syndrome

Relateret indhold
07 feb - 
Aktier/middag: Lundbeck og Novozymes i top og bund efte..
07 feb - 
Aktier/åbning: Fremgang efter regnskaber fra kvartet af..
07 feb - 
Aktier/tendens: Store regnskaber før åbning med udsigt ..
Relateret debat
24 feb - 
Ukraine - Det er helt rigtigt at der findes dopamin ago..
23 feb - 
YEZ - med de kurs targets der er på aktien pt. og..
23 feb - 
Omkring år 2005/6 kom Stada Arzneimittel med et e..

Company announcement - No. 48/2017

U.S. FDA grants orphan drug designation to glepaglutide for the treatment of short bowel syndrome

Copenhagen, Denmark, October 24, 2017 - The U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has granted an orphan drug designation to glepaglutide for the treatment of the rare disease short bowel syndrome (SBS)*. Glepaglutide is a Zealand-invented long-acting GLP-2 analog that may offer a treatment option for patients with reduced or complete loss of intestinal function. Glepaglutide has been shown to reduce fecal wet weight output as well as indicated increases in both energy, fluid and electrolyte absorption in SBS patients in a Phase 2 trial. Interactions with U.S. and EU regulatory authorities are planned with the aim of moving glepaglutide into Phase 3 clinical trials in 2018.

Britt Meelby Jensen, President and CEO of Zealand, comments:

"The orphan drug designation is great news, both for Zealand and for the patients suffering from short bowel syndrome. The orphan drug designation for glepaglutide enables us to have a closer and more frequent dialogue with the FDA throughout our late stage clinical development. Glepaglutide is one of Zealand's leading product candidates, which we are developing all the way to market, and this designation is an important step for us in our efforts to ensure an efficient path to registration and patient access."

The United States Congress passed the Orphan Drug Act in 1983 to provide incentives for industry investment in treatments for rare conditions. Companies that receive orphan drug designation for their products qualify for various incentives including tax credits for clinical trial costs, relief from prescription drug user fees and the potential for seven years of market exclusivity after the drug is approved.

Short bowel syndrome

Short bowel syndrome (SBS) is a life-threatening and complex chronic severe condition associated with reduced or complete loss of intestinal function. In adults, the main underlying causes of SBS are major intestinal surgery following Crohn's disease, ischemia, radiation damage and surgery. It is estimated that 20,000-40,000 patients are affected by SBS in the U.S. and Europe. The most severely affected people are dependent on daily parenteral support. This requires them to be connected to infusion lines and pumps, which pose significant restrictions on their ability to engage in daily activities.

For further information, please contact:

Britt Meelby Jensen, President and CEO

Tel.: +45 51 67 61 28, e-mail: bmj@zealandpharma.com

Mats Blom, Executive Vice President and Chief Financial Officer

Tel.: +45 31 53 79 73, e-mail: mabl@zealandpharma.com

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen and New York: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under license collaborations with Sanofi and Boehringer Ingelheim as well as a pipeline of internal product candidates focusing on specialty gastrointestinal and metabolic diseases.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the Company's business and activities, please visit www.zealandpharma.com or follow us on Twitter @ZealandPharma or LinkedIn.

*https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?

cfgridkey=539216 

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/8adcfbfe-79c2-43d3-a199-5c4e6afd0efd

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
23 feb
ZEAL
Jeg har tildigere her på EI rapporteret at Soliqua ville blive lanceret i Sydkorea. Nu har Sanofi af..
25
23 feb
ZEAL
Sanofi og  har for et par dage siden oplyst på clinicaltrial.gov at de starter studiet «LixiPark» me..
14
19 feb
ZEAL
Tror lige Zealand har opdateret deres kommende begivenheder. Bliver spændende i 2018   HELE 13 begiv..
8
22 feb
ZEAL
Der var så dejligt ude på landet; det var sommer, kornet stod gult, havren grøn, høet var rejst i st..
4
21 feb
ZEAL
I forlængelse af nyheden omkring afslutningen på fase 3 studiet med Dasiglucagon, har jeg fundet abs..
4
21 feb
ZEAL
Zealand Pharma Press Release Press release - No. 5/2018 Zealand Pharma reports completion of the f..
4
21 feb
ZEAL
Nu fortsætter personfnidder,   (dig med dit forfølgelsesvanvid og din afhængighed, kan du jo bare sk..
3
23 feb
ZEAL
Flot indlæg EliotS Du gør altid et kæmpe arbejde med aktierne og er et stort aktiv for EI. Håber ..
2
20 feb
ZEAL
Company announcement - No. 04 / 2018 Zealand Pharma and UniQuest collaborate to develop novel drug ..
2
20 feb
ZEAL
https://cws.huginonline.com/Z/136974/PR/201802/2170158_5.html
2

Aktier/tendens: William Demant kan tage fokus i grøn åbning

23-02-2018 08:27:52
Der er udsigt til stigninger fredag morgen, når aktiemarkedet herhjemme åbner. Fra åbningen kan William Demant igen tage fokus, efter at selskabet har fået hævet kursmålet af en stribe finanshuse ovenpå torsdagens positive regnskab. I USA lukkede S&P 500 torsdagens handel med et plus på 0,2 pct., mens også Dow Jones lukkede med en gevinst på 0,7 pct. Til gengæld faldt Nasdaq med 0,1 pct. Futures f..

Aktier/middag: Genmab buldrer frem med WDH og ISS som følgesvende

22-02-2018 11:40:57
Biotekselskabet Genmab ligger helt i top i det danske eliteindeks torsdag middag efter at have præsenteret regnskab onsdag aften. Også ISS og William Demant, der begge kom med regnskab for fjerde kvartal torsdag morgen, er med i toppen.Men det er onsdagens regnskab fra Genmab, der trækker den helt store opmærksomhed, efter at biotekselskabet gjorde markedets bekymringer over en mulig skuffende pro..

ISS: Salget vokser mens bundlinjen skrumper

22-02-2018 08:39:00
ISS kan se bundlinjen falde tilbage i 2017 sammenlignet med i 2016, selvom selskabet er vokset på salget.Omsætningen i selskabet voksede til 79.912 mio. kr. i 2017, mens omsætningen udgjorde 78.658 mio. kr. i 2016.Omvendt steg nettoresultatet i 2017 til 2007 mio. kr. mod 2220 mio. kr. året før.Af regnskabet fremgår det, at årsagen til at bundlinjen ikke vokser med toplinjen, blandt andet er ekster..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Zealand Pharma A/S 96,50 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
25. februar 2018 12:22:02
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: ReleaseBuild_20180222.1 - EUROWEB5 - 2018-02-25 12:22:02 - 2018-02-25 12:22:02 - 1 - Website: OKAY